Roche’s Gazyva Meets Primary Endpoint in Phase III ALLEGORY Study, Showing Significant Disease Control in Lupus
Roche’s Phase III ALLEGORY trial reveals that Gazyva plus standard therapy helped 76.7% of SLE patients achieve significant clinical improvement. New data published in NEJM highlights Gazyva’s potential to redefine the standard of care in lupus by preventing organ damage and reducing steroid dependency.
